How Up Hail is Empowering Commuters

 

Up Hail is revolutionizing commuting, allowing commuters to compare taxi, rideshare and bikeshare fees, among other potential options, to gain greater understanding and insight into what the best option is for their unique circumstance and needs.

The service has been particularly useful in light of the growth of bikesharing, with a recent study by Dafeng Xu from the University of Washington’s Evans School of Public Policy and Governance asserting a rise in the practice from 2008-2016, especially in urban areas with bikeshare programs.

The study reported that, in urban communities with a bikesharing program, commuters chose bikes about 20% more often.

On this episode of MarketScale Live, Up Hail Founder Avi Wilensky joined Voice of B2B Daniel Litwin to discuss this growth, how it’s been impacted by the COVID-19 pandemic, and the role Up Hail is playing in helping users manage growing commuting options.

For now, though, it’s still a matter of focusing on how the industry can recover from the impact of the pandemic, which has commuters worried about options leveraged by fellow commuters.

In fact, Wilensky said, from November 16, 2019 to June 16 of this year, 204 of Up Hail users clicked out from our site to sign up for Bird, Lime, Spin, or Jump providers.

Although Wilensky admits that sample is not very large, the data derived from those users indicates a clear decline in March and remain low without a recovery we are seeing in the ridesharing space among companies like Uber and Lyft. Up Hail’s data is consistent with Google Trends, which show the same decline without recovery.

“What we’ve seen is that, since March 2 or so when the state of emergency started or the pandemic was declared, we’ve seen a slight decline in e-scooters and bikeshare selections on our site,” Wilensky said. “Right now, it seems like it’s at its low, and it hasn’t recovered yet.”

Moving forward, Wilensky said he feels price will be more important than pandemic-related fears, particularly as the world moves toward a new normal.

“I think that consumers tend to be more price-driven rather than fear-driven, and people have a budget in mind when it comes from getting from point A to point B,” he said. “People factor that in a lot more than, in my opinion, the risk of getting a disease from a transportation option. … I think, for the most part, price still wins.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More